BRAF and neoplasm: However, very limited response to this same drug was observed in colorectal cancer studies (41, 42) that revealed that BRAFV600E tumor cells presented a rapid feedback activation of EGFR expression that mediated resistance to BRAF inhibitors (43, 44).